Gene therapy biotech Capsida lays off workers after expanding AbbVie pact, adding Lilly collab

Gene ther­a­py start­up Cap­si­da Bio­ther­a­peu­tics said it is lay­ing off em­ploy­ees, months af­ter un­veil­ing two Big Phar­ma part­ner­ships that brought in $125 mil­lion.

Cap­si­da CEO Pe­ter Anas­ta­siou de­clined to com­ment on the num­ber of em­ploy­ees im­pact­ed. At the end of May, Cap­si­da had 138 em­ploy­ees, per a tal­ly from da­ta firm Pitch­Book.

The Thou­sand Oaks, CA-based start­up fol­lows some of its gene ther­a­py peers and oth­er fledg­ling drug de­vel­op­ers by down­siz­ing in the past 18 months, with many cit­ing the state of fi­nanc­ing for the in­dus­try’s young batch of com­pa­nies.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN